Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development.

Ayoun Alsoud, Rami; Svensson, Robin J; Svensson, Elin M; Gillespie, Stephen H; Boeree, Martin J; Diacon, Andreas H; Dawson, Rodney; Aarnoutse, Rob E; Simonsson, Ulrika S H

Ayoun Alsoud, Rami; Svensson, Robin J; Svensson, Elin M; Gillespie, Stephen H; Boeree, Martin J; Diacon, Andreas H; Dawson, Rodney; Aarnoutse, Rob E; Simonsson, Ulrika S H.

Afiliación

Ayoun Alsoud R; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Svensson RJ; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Svensson EM; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Gillespie SH; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
Boeree MJ; Division of Infection and Global Health, School of Medicine, University of St Andrews, St Andrews, United Kingdom.
Diacon AH; Department of Lung Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Dawson R; TASK Applied Science, Cape Town, South Africa.
Aarnoutse RE; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Simonsson USH; University of Cape Town Lung Institute, Cape Town, South Africa.

Front Pharmacol ; 14: 1067295, 2023.

Article en En | MEDLINE | ID: mdl-36998606

Palabras clave

CFU; TTP; biomarker; rifampicin; tuberculosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google